瑞舒伐他汀对不稳定型心绞痛患者PCI术后心肌损伤的保护作用

目的探讨瑞舒伐他汀在不稳定型心绞痛（UAP）经皮冠状动脉介入（PCI）术中对心肌损伤的保护作用。方法94例经PCI治疗的UAP患者随机分为观察组（n=47）与对照组（n=47），观察组在常规治疗基础上给予瑞舒伐他汀治疗，对照组在常规治疗基础上给予阿托伐他汀治疗，对比2组患者心肌损伤情况。结果2组患者术前肌酸激酶同工酶（CK-MB）、心肌肌钙蛋白I（cTnI）、人心型脂肪酸结合蛋白（h-FABP）以及超敏C反应蛋白（hs—CRP）及氧化亚氮（N0）比较差异均无统计学意义（P〉0．05）。术后2个月时，观察组上述5项指标均无显著改变（P〉0．05）；对照组CK-MB、cTnI、h-FABP及hs-cRP均显著高于术前（P〈0．01），术后NO显著低于术前（P〈0．01）。结论瑞舒伐他汀对UAP患者PCI术后心肌损伤具有有效的保护作用，安全可靠，值得推广。

Protective effect of rosuvastatin on postoperative myocardial injury in unstable angina patients with PCI

Objective To explore the protective effect of rosuvastatin on postoperative my- ocardial injury in UAP patients with PCI. Methods 94 patients with UAP treated by PCI were di- vided into the observation group （ n = 47） and the control group （ n = 47）. The observation group was treated with rosuvastatin on the basis of conventional therapy, and the control group was treat- ed with atorvastatin. Myocardial injury indicators were compared between the two groups. Results There were no significant differences of CK-MB, cTnI, h-FABP, hs-CRP and NO before PCI between two groups（P 〉 0.05） ; two months after PCI, there were no significant differences of five indicators mentioned above in the observation group（P 〉0.05）; levels of CK-MB, cTnI, h-FABP and hs-CRP after PCI increased significantly in the control group （P 〈 0.01）, while NO reduced significantly （P 〈 0.01）. Conclusion Rosuvastatin can effectively protect myocardial injury after PCI in patients with UAP, so it is worthy of popularization.